Widespread CD4+ T-cell reactivity to novel hTERT epitopes following vaccination of cancer patients with a single hTERT peptide GV1001.
about
Telomere and Telomerase Therapeutics in CancerInterest of Tumor-Specific CD4 T Helper 1 Cells for Therapeutic Anticancer VaccineThe Telomerase-Derived Anticancer Peptide Vaccine GV1001 as an Extracellular Heat Shock Protein-Mediated Cell-Penetrating PeptideCross-Reactivity, Epitope Spreading, and De Novo Immune Stimulation Are Possible Mechanisms of Cross-Protection of Nonvaccine Human Papillomavirus (HPV) Types in Recipients of HPV Therapeutic VaccinesPhase I/IIa clinical trial of a novel hTERT peptide vaccine in men with metastatic hormone-naive prostate cancer.Highly optimized DNA vaccine targeting human telomerase reverse transcriptase stimulates potent antitumor immunity.Generation of more effective cancer vaccinesTelomere maintenance mechanisms in cancer: clinical implicationsTrial Watch: Peptide-based anticancer vaccines.Inhibition of UBE2D3 expression attenuates radiosensitivity of MCF-7 human breast cancer cells by increasing hTERT expression and activity.Overexpressed oncogenic tumor-self antigensMUC1 Vaccines, Comprised of Glycosylated or Non-Glycosylated Peptides or Tumor-Derived MUC1, Can Circumvent Immunoediting to Control Tumor Growth in MUC1 Transgenic Mice.Establishing the pig as a large animal model for vaccine development against human cancerProtective effect of telomerase-based 16-mer peptide vaccine (GV1001) on inferior epigastric island skin flap survivability in ischaemia-reperfusion injury rat model.Immunoprevalence and magnitude of HLA-DP4 versus HLA-DR-restricted spontaneous CD4(+) Th1 responses against telomerase in cancer patients.Systems vaccinology for cancer vaccine development.Heparan Sulfate Proteoglycans Promote Telomerase Internalization and MHC Class II Presentation on Dendritic Cells.Immune response and long-term clinical outcome in advanced melanoma patients vaccinated with tumor-mRNA-transfected dendritic cells.MHC class II tetramer analyses in AE37-vaccinated prostate cancer patients reveal vaccine-specific polyfunctional and long-lasting CD4(+) T-cellsViral based vaccine TG4010 induces broadening of specific immune response and improves outcome in advanced NSCLCT-helper cell receptors from long-term survivors after telomerase cancer vaccination for use in adoptive cell therapy.An oncofetal antigen, IMP-3-derived long peptides induce immune responses of both helper T cells and CTLs.Trial Watch: Peptide vaccines in cancer therapy.Trial Watch: Anticancer radioimmunotherapy.Promising immunotherapy for prostate cancer.Protective effects of GV1001 on myocardial ischemia‑reperfusion injury.Bladder cancer-associated cancer-testis antigen-derived long peptides encompassing both CTL and promiscuous HLA class II-restricted Th cell epitopes induced CD4+ T cells expressing converged T-cell receptor genes in vitro.New Approaches in Immunotherapy for the Treatment of Lung Cancer.Targeting Head and Neck Cancer by Vaccination.Immunological factors influencing clinical outcome in lung cancer patients after telomerase peptide vaccination.Frequency of Class I and II HLA alleles in patients with lung cancer according to chemotherapy response and 5-year survival
P2860
Q26744808-8C18351D-F81B-4EC1-A91D-E7FE20905E15Q26782583-496A6842-1546-4A12-A310-A821513C2D47Q28076133-51264D02-02FD-4CF5-A4E3-BF7373BD628CQ28085724-03275FC2-47B1-4952-B340-6279BAA15E68Q33440805-6675CA7B-C641-4053-8029-770728D2BEA1Q33897405-E6D92391-2A90-47D1-AD3E-829F1F6BCA22Q34169981-6636E770-935A-4E9B-8464-373C7C2FF353Q34426966-DBE4D73A-1FF0-4F22-B2E6-4ACB9C47324CQ34483345-4EDCB836-B628-462C-A86F-F5290122C079Q34760621-8025AAB4-F47B-4947-B119-187F1CDCFE82Q35886756-BF0FEFD2-B18D-4E36-B05D-11819BCEB96CQ35898801-013B1DCA-CC32-495F-98E7-3EDBEAF3EDFFQ36097327-2C9C9166-492D-4A76-97CA-E32ACCD73ABEQ36145291-6F85770F-0413-4828-B693-AB02DC92745DQ37012876-4DA85AB1-0C45-4343-B952-B69DBAED5C76Q38207141-53F5082B-EFB4-425F-B433-23EF669A77A5Q38754328-FFAA2172-4385-4173-B149-7B121D7848C4Q39079690-FDC2100E-C7EA-475C-8786-7CB557241360Q40987678-6589FE16-3997-4699-8708-D9836ED8D9C0Q41706953-50EC01D6-E214-4302-B15E-F0CD7A5D6466Q42333881-8A63690D-7212-4F6E-93CC-8C19908584CFQ42427592-63B89682-AE01-44F6-BE7A-3788B214AA11Q42734544-824DDE30-80F5-4238-A36D-55EF62C86DCBQ42847992-E7260CD4-6E80-469C-9257-A0934B79FF54Q47566793-1B451434-EEAF-436C-8E41-837F7EE948E9Q49852588-CC4832C1-7A8D-4940-9B3E-7483DB5D22CDQ52597543-485CC648-3587-4F19-BD81-1CF4B3CD4B57Q52871134-893CA54E-4C78-4E57-89FD-AD13824CE8AEQ54217605-C1FA92F8-F10A-4751-9F94-90B0E4C1BAB8Q54238337-081816C7-9C55-443F-8E0A-F7B712A1B5ACQ56945687-379D5695-7A39-4DC2-BA78-AE090C65BDE5
P2860
Widespread CD4+ T-cell reactivity to novel hTERT epitopes following vaccination of cancer patients with a single hTERT peptide GV1001.
description
2012 nî lūn-bûn
@nan
2012年の論文
@ja
2012年論文
@yue
2012年論文
@zh-hant
2012年論文
@zh-hk
2012年論文
@zh-mo
2012年論文
@zh-tw
2012年论文
@wuu
2012年论文
@zh
2012年论文
@zh-cn
name
Widespread CD4+ T-cell reactiv ...... a single hTERT peptide GV1001.
@ast
Widespread CD4+ T-cell reactiv ...... a single hTERT peptide GV1001.
@en
type
label
Widespread CD4+ T-cell reactiv ...... a single hTERT peptide GV1001.
@ast
Widespread CD4+ T-cell reactiv ...... a single hTERT peptide GV1001.
@en
prefLabel
Widespread CD4+ T-cell reactiv ...... a single hTERT peptide GV1001.
@ast
Widespread CD4+ T-cell reactiv ...... a single hTERT peptide GV1001.
@en
P2093
P2860
P356
P1433
P1476
Widespread CD4+ T-cell reactiv ...... a single hTERT peptide GV1001.
@en
P2093
Anne-Marie Rasmussen
Else-Marit Inderberg-Suso
Kari Lislerud
Sissel Trachsel
P2860
P304
P356
10.4161/ONCI.20426
P577
2012-08-01T00:00:00Z